These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 8486199)

  • 1. Long-acting injectable bromocriptine (Parlodel LAR) in the chronic treatment of prolactin-secreting macroadenomas.
    Lengyel AM; Mussio W; Imamura P; Vieira JG; Lancranjan I
    Fertil Steril; 1993 May; 59(5):980-7. PubMed ID: 8486199
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effectiveness of a long-acting injectable form of bromocriptine in patients with prolactin and growth hormone secreting macroadenomas.
    Tsagarakis S; Tsiganou E; Tzavara I; Nikolou H; Thalassinos N
    Clin Endocrinol (Oxf); 1995 Jun; 42(6):593-9. PubMed ID: 7634499
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long term therapy of patients with macroprolactinoma using repeatable injectable bromocriptine.
    Ciccarelli E; Miola C; Grottoli S; Avataneo T; Lancranjan I; Camanni F
    J Clin Endocrinol Metab; 1993 Feb; 76(2):484-8. PubMed ID: 8432794
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Parlodel LAR in the treatment of macroprolactinomas.
    Kocijancic A; Prezelj J; Vrhovec I; Lancranjan I
    Acta Endocrinol (Copenh); 1990 Feb; 122(2):272-6. PubMed ID: 2316314
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chronic treatment with parlodel LAR of patients with prolactin-secreting tumours. Different responsiveness of micro- and macroprolactinomas.
    Maraschini C; Moro M; Masala A; Toja P; Alagna S; Brunani A; Rovasio PP; Ginanni A; Lancranjan I; Cavagnini F
    Acta Endocrinol (Copenh); 1991 Nov; 125(5):494-501. PubMed ID: 1759539
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term treatment with a new repeatable injectable form of bromocriptine, Parlodel LAR, in patients with tumorous hyperprolactinemia.
    Ciccarelli E; Miola C; Avataneo T; Camanni F; Besser GM; Grossman A
    Fertil Steril; 1989 Dec; 52(6):930-5. PubMed ID: 2591571
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rapid and long-lasting suppression of prolactin secretion and shrinkage of prolactinomas after injection of long-acting repeatable form of bromocriptine (Parlodel LAR).
    Schettini G; Lombardi G; Merola B; Colao A; Miletto P; Caruso E; Lancranjan I
    Clin Endocrinol (Oxf); 1990 Aug; 33(2):161-9. PubMed ID: 2225475
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment with long acting repeatable bromocriptine (Parlodel-LAR*) in patients with macroprolactinomas: long-term study in 29 patients.
    Jamrozik SI; Bennet AP; James-Deidier A; Tremollieres F; Saint-Martin F; Dumoulin S; Valat-Coustols M; de Glisezinski I; Tremoulet M; Manelfe C; Louvet JP
    J Endocrinol Invest; 1996; 19(7):472-9. PubMed ID: 8884542
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of macroprolactinomas with the long-acting and repeatable form of bromocriptine: a report on 29 cases.
    Beckers A; Petrossians P; Abs R; Flandroy P; Stadnik T; de Longueville M; Lancranjan I; Stevenaert A
    J Clin Endocrinol Metab; 1992 Jul; 75(1):275-80. PubMed ID: 1619019
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Control of prolactin-secreting macroadenomas with parenteral, long-acting bromocriptine in 30 patients treated for up to 3 years.
    Haase R; Jaspers C; Schulte HM; Lancranja I; Pfingsten H; Orri-Fend M; Reinwein D; Benker G
    Clin Endocrinol (Oxf); 1993 Feb; 38(2):165-76. PubMed ID: 8435897
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A long-acting repeatable form of bromocriptine as long-term treatment of prolactin-secreting macroadenomas: a multicenter study.
    Brue T; Lancranjan I; Louvet JP; Dewailly D; Roger P; Jaquet P
    Fertil Steril; 1992 Jan; 57(1):74-80. PubMed ID: 1730334
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Long-acting and repeatable dose bromocriptine in the prolonged treatment of prolactinoma].
    Pereira JL; García-Luna PP; Leal-Cerro A; Cortés A; Trujillo F; Villamil F; Vaquero F; Revuelta M; Astorga R
    Med Clin (Barc); 1994 Jun; 103(2):59-64. PubMed ID: 8051973
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison among different dopamine-agonists of new formulation in the clinical management of macroprolactinomas.
    Colao A; Merola B; Sarnacchiaro F; Di Sarno A; Landi ML; Marzullo P; Cerbone G; Ferone D; Lombardi G
    Horm Res; 1995; 44(5):222-8. PubMed ID: 8582715
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New long-acting bromocriptine (Parlodel MR and Parlodel LAR) in the treatment of pituitary tumours with hyperprolactinemia.
    Zgliczyński W; Zgliczyński S; Makowska A; Słowinska-Srzednicka J; Janik J; Jeske W; Walecki J
    Endokrynol Pol; 1992; 43(3):234-41. PubMed ID: 1345564
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Primary treatment of macroprolactinomas with Parlodel LAR.
    van 't Verlaat JW; Lancranjan I; Hendriks MJ; Croughs RJ
    Acta Endocrinol (Copenh); 1988 Sep; 119(1):51-5. PubMed ID: 3414319
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Shrinkage of pituitary PRL-secernent adenoma after short-term treatment with bromocriptine long-acting repeatable injections.
    Paoletti AM; Cagnacci A; Mais V; Ajossa S; Guerriero S; Murgia C; Depau GF; Serra GG; Melis GB
    Clin Exp Obstet Gynecol; 1994; 21(2):124-8. PubMed ID: 8070116
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prolactin-secreting macroadenomas in adolescents. Response to bromocriptine therapy.
    Tyson D; Reggiardo D; Sklar C; David R
    Am J Dis Child; 1993 Oct; 147(10):1057-61. PubMed ID: 8213676
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-lasting suppression of prolactin secretion and rapid shrinkage of prolactinomas after a long-acting, injectable form of bromocriptine.
    Montini M; Pagani G; Gianola D; Pagani MD; Salmoiraghi M; Ferrari L; Lancranjan I
    J Clin Endocrinol Metab; 1986 Jul; 63(1):266-8. PubMed ID: 3711262
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oral and injectable long-lasting bromocriptine preparations in hyperprolactinemia: comparison of their prolactin lowering activity, tolerability and safety.
    Merola B; Colao A; Caruso E; Sarnacchiaro F; Briganti F; Lancranjan I; Lombardi G; Schettini G
    Gynecol Endocrinol; 1991 Dec; 5(4):267-76. PubMed ID: 1796748
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effectiveness of a single injectable dose of bromocriptine long acting in the treatment of macroprolactinomas.
    Schettini G; Lombardi G; Merola B; Miletto P; Fariello C; Cirillo S; Fusco R; Lancranjan I
    J Endocrinol Invest; 1988 Jan; 11(1):47-51. PubMed ID: 3361075
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.